# A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

> **NCT05395533** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Zhejiang Teruisi Pharmaceutical Inc.** · enrollment: 147 (actual)

## Conditions studied

- CD20-positive B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Recombinant CD20 monoclonal antibody-MMAE conjugte for injection

## Key facts

- **NCT ID:** NCT05395533
- **Lead sponsor:** Zhejiang Teruisi Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-08
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05395533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05395533, "A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05395533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*